Search Results

You are looking at 61 - 70 of 800 items for :

  • "metastases" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

James L. Mohler, Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D’Amico, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Gary R. MacVicar, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, Sylvia Richey, Mack Roach III, Eric Rohren, Stan Rosenfeld, Eric J. Small, Sandy Srinivas, Cy Stein, Seth A. Strope, Jonathan Tward, Patrick C. Walsh, Dorothy A. Shead, and Maria Ho

. Most patients with castration-recurrent or -resistant prostate cancer (CRPC) die of bone metastases and related complications. The recently approved radium-223 is the first bone-targeting agent to demonstrate a survival benefit in these patients

Full access

Steven S. Brem, Philip J. Bierman, Henry Brem, Nicholas Butowski, Marc C. Chamberlain, Ennio A. Chiocca, Lisa M. DeAngelis, Robert A. Fenstermaker, Allan Friedman, Mark R. Gilbert, Deneen Hesser, Larry Junck, Gerald P. Linette, Jay S. Loeffler, Moshe H. Maor, Madison Michael, Paul L. Moots, Tara Morrison, Maciej Mrugala, Louis Burt Nabors, Herbert B. Newton, Jana Portnow, Jeffrey J. Raizer, Lawrence Recht, Dennis C. Shrieve, Allen K. Sills Jr, Frank D. Vrionis, and Patrick Y. Wen

. Between 20% and 40% of patients with systemic cancer will develop brain metastases. 3 NOTE: This manuscript highlights only a portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Central Nervous System Cancers. Please refer

Full access

Douglas B. Johnson, Riyue Bao, Kristin K. Ancell, Anthony B. Daniels, Deborah Wallace, Jeffrey A. Sosman, and Jason J. Luke

metastases and 2 had prior therapies (see supplemental eAppendix 1 , available online with this article at JNCCN.org ). Of these 5 patients, 1 had a complete response (CR; ongoing at 25.5 months), and no partial responses were observed (response rate, 20

Full access

Estanislao Arana, Francisco M. Kovacs, Ana Royuela, Beatriz Asenjo, Úrsula Pérez-Ramírez, Javier Zamora, and the Spanish Back Pain Research Network Task Force for the Improvement of Inter-Disciplinary Management of Spinal Metastasis

Background Malignant or metastatic spinal cord compression of the thecal sac is a devastating medical emergency presented by 5% to 20% of patients with spinal metastases. 1 It can be caused by vertebral collapse, but is usually provoked by

Full access

Angela Pecoraro, Giuseppe Rosiello, Stefano Luzzago, Marina Deuker, Franciska Stolzenbach, Zhe Tian, Shahrokh F. Shariat, Fred Saad, Alberto Briganti, Anil Kapoor, Cristian Fiori, Francesco Porpiglia, and Pierre I. Karakiewicz

better elucidate the distribution of age, sex, histologic subtype, and FG, in addition to assessing the rates of synchronous metastases in a large contemporary population-based cohort. We hypothesized that most patients harbored FG1–2 tumors, either the

Full access

Kathleen Harnden and Kimberly Blackwell

Bisphosphonates are an integral part of treatment for bone metastases in many malignancies, including breast cancer. Bone metastases can have devastating consequences, including severe pain, fractures, hypercalcemia, and spinal cord compression

Full access

Wen-Zhuo He, Wan-Ming Hu, Fang Wang, Yu-Ming Rong, Lin Yang, Qian-Kun Xie, Yuan-Zhong Yang, Chang Jiang, Hui-Juan Qiu, Jia-Bin Lu, Bei Zhang, Pei-Rong Ding, Xiao-Jun Xia, Jian-Yong Shao, and Liang-Ping Xia

, particularly genetic discordances between the primary and the metastatic sites. 3 – 6 Moreover, oxidative DNA damage and some chemokines were significantly higher in metastases than in primary tumors, 7 , 8 and the level of tumor-infiltrating lymphocytes and

Full access

Louis Burt Nabors, Mario Ammirati, Philip J. Bierman, Henry Brem, Nicholas Butowski, Marc C. Chamberlain, Lisa M. DeAngelis, Robert A. Fenstermaker, Allan Friedman, Mark R. Gilbert, Deneen Hesser, Matthias Holdhoff, Larry Junck, Ronald Lawson, Jay S. Loeffler, Moshe H. Maor, Paul L. Moots, Tara Morrison, Maciej M. Mrugala, Herbert B. Newton, Jana Portnow, Jeffrey J. Raizer, Lawrence Recht, Dennis C. Shrieve, Allen K. Sills Jr, David Tran, Nam Tran, Frank D. Vrionis, Patrick Y. Wen, Nicole McMillian, and Maria Ho

patients with systemic cancer will develop brain metastases. 3 Principles of Management Primary and metastatic brain tumors are a heterogeneous group of neoplasms with varied outcomes and management strategies. Primary brain tumors range from

Full access

Stephen R. Grant, Benjamin D. Smith, Lauren E. Colbert, Qunyh-Nhu Nguyen, James B. Yu, Steven H. Lin, and Aileen B. Chen

Background Bone metastases are common in patients presenting with metastatic non–small cell lung cancer (NSCLC) and are often treated with palliative radiation therapy. 1 There exists wide practice variability in palliative treatment

Full access

Stephen R. Grant, Benjamin D. Smith, Lauren E. Colbert, Qunyh-Nhu Nguyen, James B. Yu, Steven H. Lin, and Aileen B. Chen

Background Bone metastases are common in patients presenting with metastatic non–small cell lung cancer (NSCLC) and are often treated with palliative radiation therapy. 1 There exists wide practice variability in palliative treatment